Trial Profile
A 24-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppression in patients with quiescent, non-infectious intermediate, posterior or panuveitis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 Mar 2018
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Intermediate uveitis; Panuveitis; Posterior uveitis
- Focus Therapeutic Use
- Acronyms ENDURE
- Sponsors Novartis
- 18 Dec 2014 New trial record